{"id":37576,"date":"2021-07-16T11:50:00","date_gmt":"2021-07-16T04:50:00","guid":{"rendered":"https:\/\/www.xinwengao.com\/cn\/pr\/2021071611500037576"},"modified":"2021-07-16T21:37:58","modified_gmt":"2021-07-16T13:37:58","slug":"%e5%92%8c%e9%bb%84%e5%8c%bb%e8%8d%af%e5%90%91%e6%ac%a7%e6%b4%b2%e8%8d%af%e5%93%81%e7%ae%a1%e7%90%86%e5%b1%80%e6%8f%90%e4%ba%a4%e7%b4%a2%e5%87%a1%e6%9b%bf%e5%b0%bc%e7%9a%84%e4%b8%8a%e5%b8%82%e8%ae%b8","status":"publish","type":"post","link":"https:\/\/www.xinwengao.com\/cn\/pr\/2021071611500037576","title":{"rendered":"\u548c\u9ec4\u533b\u836f\u5411\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\u63d0\u4ea4\u7d22\u51e1\u66ff\u5c3c\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u5e76\u83b7\u786e\u8ba4"},"content":{"rendered":"<p><p><span class=\"xn-subheadline\">&#8211; \u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\u5f00\u59cb\u5ba1\u8bc4\u7d22\u51e1\u66ff\u5c3c\u7528\u4e8e\u6cbb\u7597\u665a\u671f\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7 &#8211;<\/span><\/p>\n<p><span class=\"xn-subheadline\">-\u7ee7\u7d22\u51e1\u66ff\u5c3c\u4e8e\u4e2d\u56fd\u4e0a\u5e02\u4ee5\u53ca\u7f8e\u56fd\u7684\u4e0a\u5e02\u7533\u8bf7\u8fdb\u5165\u5ba1\u8bc4\u9636\u6bb5\u540e\uff0c\u8fdb\u4e00\u6b65\u6269\u5927\u4e86\u5176\u6f5c\u5728\u5168\u7403\u53ef\u53ca\u8303\u56f4-<\/span><\/p>\n<table border=\"0\" cellspacing=\"10\" cellpadding=\"5\" align=\"right\">\n<tbody>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/www.xinwengao.com\/cn\/wp-content\/uploads\/HUTCHMED_Logo-4.jpg\" border=\"0\" alt=\"\" title=\"logo\" hspace=\"0\" vspace=\"0\" width=\"118\" \/><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span id=\"spanHghlt0c6c\">\u9999\u6e2f<\/span>2021\u5e747\u670816\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u548c\u9ec4\u533b\u836f\uff08\u4e2d\u56fd\uff09\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/home\/\" rel=\"nofollow noopener\">\u548c\u9ec4\u533b\u836f<\/a>\u201d\u6216\u201cHUTCHMED\u201d\uff09\uff08\u7eb3\u65af\u8fbe\u514b\/\u4f26\u6566\u8bc1\u4ea4\u6240\uff1aHCM\uff1b\u9999\u6e2f\u4ea4\u6613\u6240\uff1a13\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08\u201cEMA\u201d\uff09\u5df2\u786e\u8ba4\u5e76\u53d7\u7406\u7d22\u51e1\u66ff\u5c3c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u548c\u80f0\u817a\u5916\uff08\u975e\u80f0\u817a\uff09\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08NET\uff09\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\uff08MAA\uff09\u3002EMA \u5df2\u786e\u8ba4\u63d0\u4ea4\u6750\u6599\u7684\u5b8c\u6574\u6027\uff0c\u5e76\u4e14\u5df2\u51c6\u5907\u597d\u542f\u52a8\u6b63\u5f0f\u7684\u5ba1\u8bc4\u7a0b\u5e8f\u3002<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<\/p><\/div>\n<\/p>\n<p>\u8be5\u7533\u8bf7\u63d0\u4ea4\u662f\u9075\u5faa\u4e86 EMA \u4eba\u7528\u836f\u54c1\u59d4\u5458\u4f1a\uff08\u201cCHMP\u201d\uff09\u63d0\u4f9b\u7684\u79d1\u5b66\u5efa\u8bae\uff0c\u5176\u7ed3\u8bba\u4e3a\uff1a\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u80f0\u817a\u548c\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u4e24\u9879\u6210\u529f\u7684\u4e2d\u56fd&nbsp;III \u671f\u7814\u7a76\uff08SANET-p<span id=\"spanHghlt84ea\"><sup>[1]<\/sup><\/span>&nbsp;\u53ca SANET-ep<span id=\"spanHghlt8faa\"><sup>[2]<\/sup><\/span>&nbsp;\uff0c\u4e24\u9879\u7814\u7a76\u7ed3\u679c\u5747\u5df2\u4e8e\u300a\u67f3\u53f6\u5200<span id=\"spanHghlted99\">&#8211;<\/span>\u80bf\u7624\u5b66\u300b\u671f\u520a\u4e0a\u520a\u767b\uff09\u4ee5\u53ca\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u7f8e\u56fd\u975e\u80f0\u817a\u548c\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u73b0\u6709\u6570\u636e\uff0c\u53ef\u4ee5\u4f5c\u4e3a\u652f\u6301\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u7684\u4f9d\u636e\u3002\u548c\u9ec4\u533b\u836f\u5df2\u4e8e&nbsp;2021 \u5e74 7 \u6708 1 \u65e5\u5ba3\u5e03\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08\u201cFDA\u201d\uff09\u63d0\u4ea4\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u5e76\u83b7\u53d7\u7406\u3002<\/p>\n<p>\u548c\u9ec4\u533b\u836f\uff08\u56fd\u9645\uff09\u8463\u4e8b\u603b\u7ecf\u7406\u517c\u9996\u5e2d\u533b\u5b66\u5b98 <span class=\"xn-person\">Marek Kania<\/span> \u533b\u5b66\u535a\u58eb\u8868\u793a\uff1a\u201c\u548c\u9ec4\u533b\u836f\u7684\u521b\u65b0\u80bf\u7624\u836f\u7269\u7ba1\u7ebf\u6b63\u5728\u5168\u7403\u8303\u56f4\u5185\u53d6\u5f97\u91cd\u8981\u7684\u8fdb\u5c55\u3002\u7ee7\u7f8e\u56fd FDA <a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/fda-accepts-surufatinib-nda-for-net\/\" rel=\"nofollow noopener\">\u53d7\u7406<\/a>\u7d22\u51e1\u66ff\u5c3c\u7684\u7f8e\u56fd\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u540e\uff0c\u6211\u4eec\u76f8\u4fe1\u6b64\u6b21 EMA \u5bf9\u8be5\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u7684\u786e\u8ba4\uff0c\u8ba4\u53ef\u4e86\u76f8\u5173\u7533\u8bf7\u6750\u6599\u7684\u79d1\u5b66\u4ef7\u503c\u3002\u4eca\u5e74\u65e9\u4e9b\u65f6\u5019\uff0c\u7d22\u51e1\u66ff\u5c3c\u4e8e\u4e2d\u56fd\u4e0a\u5e02\uff0c\u4e3a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u6cbb\u7597\u65b0\u9009\u62e9\uff0c\u73b0\u5728\u6211\u4eec\u5e0c\u671b\u5f88\u5feb\u80fd\u591f\u5c06\u8fd9\u79cd\u91cd\u8981\u7684\u6cbb\u7597\u65b9\u6cd5\u5e26\u5411\u7f8e\u56fd\u548c\u6b27\u6d32\u7684\u60a3\u8005\u3002\u201d <\/p>\n<p><b>\u5173\u4e8e\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08NET\uff09<\/b><\/p>\n<p>\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u8d77\u6e90\u4e8e\u4e0e\u795e\u7ecf\u7cfb\u7edf\u76f8\u4e92\u4f5c\u7528\u7684\u7ec6\u80de\u6216\u4ea7\u751f\u6fc0\u7d20\u7684\u817a\u4f53\u3002\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u53ef\u8d77\u6e90\u4e8e\u4f53\u5185\u5404\u4e2a\u90e8\u4f4d\uff0c\u6700\u5e38\u89c1\u4e8e\u6d88\u5316\u9053\u6216\u80ba\u90e8\uff0c\u53ef\u4e3a\u826f\u6027\u6216\u6076\u6027\u80bf\u7624\u3002\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u901a\u5e38\u5206\u4e3a\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08pNET\uff09\u548c\u80f0\u817a\u5916\uff08\u975e\u80f0\u817a\uff09\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08epNET\uff09\u3002<\/p>\n<p>\u636e&nbsp;Frost &amp; Sullivan \u516c\u53f8\u4f30\u8ba1\uff0c2020 \u5e74\u7f8e\u56fd\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u65b0\u8bca\u65ad\u75c5\u4f8b\u4e3a&nbsp;19,000 \u4f8b\u3002\u57fa\u4e8e\u5168\u7403\u6d41\u884c\u75c5\u5b66\u8d8b\u52bf\u7684\u5206\u6790\uff0c\u6574\u4e2a\u6b27\u76df&nbsp;(EU) \u7684\u53d1\u75c5\u7387\u4e0e\u7f8e\u56fd\u5927\u81f4\u76f8\u8fd1\uff0c\u800c\u8be5\u5206\u6790\u540c\u65f6\u663e\u793a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u5168\u7403\u53d1\u75c5\u7387\u5448\u4e0a\u5347\u8d8b\u52bf\u3002<sup><span id=\"spanHghltfb6d\">[3]<\/span><\/sup>&nbsp;\u91cd\u8981\u7684\u662f\uff0c\u4e0e\u5176\u4ed6\u80bf\u7624\u76f8\u6bd4\uff0c\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u751f\u5b58\u671f\u76f8\u5bf9\u8f83\u957f\u3002&nbsp;\u56e0\u6b64\uff0c\u636e\u4f30\u8ba12020 \u5e74\u6cd5\u56fd\u3001\u5fb7\u56fd\u3001\u610f\u5927\u5229\u3001\u897f\u73ed\u7259\u548c\u82f1\u56fd\u7ea6\u6709&nbsp;140,000 \u540d\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u3002<span id=\"spanHghlt18d2\"><sup>[4]<\/sup><\/span> <\/p>\n<\/p>\n<\/p>\n<p><b>\u5173\u4e8e\u7d22\u51e1\u66ff\u5c3c<\/b><\/p>\n<p>\u7d22\u51e1\u66ff\u5c3c\uff08surufatinib\uff09\u662f\u4e00\u79cd\u65b0\u578b\u7684\u53e3\u670d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5177\u6709\u6297\u8840\u7ba1\u751f\u6210\u548c\u514d\u75ab\u8c03\u8282\u53cc\u91cd\u6d3b\u6027\u3002\u7d22\u51e1\u66ff\u5c3c\u53ef\u901a\u8fc7\u6291\u5236\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08VEGFR\uff09\u548c\u6210\u7ea4\u7ef4\u7ec6\u80de\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08FGFR\uff09\u4ee5\u963b\u65ad\u80bf\u7624\u8840\u7ba1\u751f\u6210\uff0c&nbsp;\u5e76\u53ef\u6291\u5236\u96c6\u843d\u523a\u6fc0\u56e0\u5b50&nbsp;1 \u53d7\u4f53\uff08CSF-1R\uff09\uff0c\u901a\u8fc7\u8c03\u8282\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de\uff0c\u4fc3\u8fdb\u673a\u4f53\u5bf9\u80bf\u7624\u7ec6\u80de\u7684\u514d\u75ab\u5e94\u7b54\u3002\u7d22\u51e1\u66ff\u5c3c\u72ec\u7279\u7684\u53cc\u91cd\u673a\u5236\u80fd\u4ea7\u751f\u534f\u540c\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u4f7f\u5176\u4e3a\u4e0e\u5176\u4ed6\u514d\u75ab\u7597\u6cd5\u7684\u8054\u5408\u4f7f\u7528\u7684\u7406\u60f3\u9009\u62e9\u3002<\/p>\n<p>\u548c\u9ec4\u533b\u836f\u76ee\u524d\u62e5\u6709\u7d22\u51e1\u66ff\u5c3c\u5728\u5168\u7403\u8303\u56f4\u5185\u7684\u6240\u6709\u6743\u5229\u3002<\/p>\n<p><b>\u7d22\u51e1\u66ff\u5c3c\u5f00\u53d1\u8ba1\u5212<\/b><\/p>\n<p><i>\u7f8e\u56fd\u4e0e<\/i><i>\u6b27<\/i><i>\u6d32\u795e\u7ecf<\/i><i>\u5185<\/i><i>\u5206\u6ccc\u7624\u7814\u7a76\uff1a<\/i>\u7d22\u51e1\u66ff\u5c3c\u7684\u7f8e\u56fd\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/fda-accepts-surufatinib-nda-for-net\/\" rel=\"nofollow noopener\">\u5df2\u4e8e 2021 \u5e74 6 \u6708\u83b7 FDA \u53d7\u7406<\/a>\uff0c\u5411 EMA \u63d0\u4ea4\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u4ea6\u4e8e&nbsp;2021 \u5e74 7 \u6708\u83b7\u786e\u8ba4\u3002\u4ee5\u4e0a\u7533\u8bf7\u5747\u662f\u57fa\u4e8e\u5df2\u5b8c\u6210\u7684 SANET-ep \u548c SANET-p \u7814\u7a76\uff0c\u4ee5\u53ca\u7d22\u51e1\u66ff\u5c3c\u5728\u7f8e\u56fd\u6cbb\u7597\u975e\u80f0\u817a\u548c\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u73b0\u6709\u6570\u636e\uff08clinicaltrials.gov \u6ce8\u518c\u53f7<span id=\"spanHghlt2b09\">\uff1a<\/span><u><a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02549937\" rel=\"nofollow noopener\">NCT02549937<\/a><\/u>\uff09\u3002\u5728\u7f8e\u56fd\uff0c\u7d22\u51e1\u66ff\u5c3c\u4e8e 2020 \u5e74 4 \u6708\u88ab\u6388\u4e88<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/surufatinib-granted-us-fda-fast-track-designations\/\" rel=\"nofollow noopener\">\u5feb\u901f\u901a\u9053\u8d44\u683c<\/a>\uff0c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u548c\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff0c\u5e76\u4e8e 2019 \u5e74 11 \u6708\u88ab\u6388\u4e88<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/surufatinib-fda-orphan-drug-designation\/\" rel=\"nofollow noopener\">\u201c\u5b64\u513f\u836f\u201d<\/a>\u8d44\u683c\uff0c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624&nbsp;\u3002<\/p>\n<p><i>\u4e2d\u56fd\u975e\u80f0\u817a\u795e\u7ecf<\/i><i>\u5185<\/i><i>\u5206\u6ccc\u7624\u7814\u7a76\uff1a<\/i>\u7d22\u51e1\u66ff\u5c3c\u4e8e 2020 \u5e74 12 \u6708 30 \u65e5\u83b7\u4e2d\u56fd\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/chi-med-announces-the-nmpa-approval-of-surufatinib-sulanda-in-china-for-epnet\/\" rel=\"nofollow noopener\">\u6279\u51c6<\/a>\u7528\u4e8e\u6cbb\u7597\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u3002\u7d22\u51e1\u66ff\u5c3c\u5728\u4e2d\u56fd\u5e02\u573a\u4ee5\u5546\u54c1\u540d\u82cf\u6cf0\u8fbe&reg;\u9500\u552e\u3002\u6b64\u83b7\u6279\u662f\u57fa\u4e8e\u4e00\u9879\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u4e2d\u56fdIII\u671f\u4e34\u5e8a\u8bd5\u9a8c SANET-ep \u7684\u7814\u7a76\u7ed3\u679c\uff08clinicaltrials.gov \u6ce8\u518c\u53f7<span id=\"spanHghlt2b09\">\uff1a<\/span><a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02588170\" rel=\"nofollow noopener\">NCT02588170<\/a>\uff09\u3002\u8be5\u7814\u7a76\u5728\u4e2d\u671f\u5206\u6790\u4e2d\u6210\u529f\u8fbe\u5230\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08\u201cPFS\u201d\uff09\u8fd9\u4e00\u9884\u8bbe\u7684\u4e3b\u8981\u7ec8\u70b9\u3002\u8be5\u7814\u7a76\u7684<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/2019-esmo-annual-meeting\/\" rel=\"nofollow noopener\">\u79ef\u6781\u7ed3\u679c<\/a>\u4e8e 2019 \u5e74\u6b27\u6d32\u80bf\u7624\u5185\u79d1\u5b66\u4f1a\uff08ESMO\uff09\u5e74\u4f1a\u4e0a\u4ee5\u53e3\u5934\u62a5\u544a\u7684\u5f62\u5f0f\u516c\u5e03\uff0c\u5e76\u4e8e 2020 \u5e74 9 \u6708\u5728\u300a\u523a\u9488<span id=\"spanHghlte275\">&#8211;<\/span>\u80bf\u7624\u5b66\u300b\u4e0a<a target=\"_blank\" href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204520304964\" rel=\"nofollow noopener\">\u53d1\u8868<\/a>\u3002<sup><span id=\"spanHghltcd7c\">[5]<\/span> <\/sup>\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u7ec4\u60a3\u8005\u7684\u4e2d\u4f4d PFS \u663e\u8457\u5ef6\u957f\u4e3a 9.2 \u4e2a\u6708\uff0c\u5b89\u6170\u5242\u7ec4\u60a3\u8005\u5219\u4e3a 3.8 \u4e2a\u6708\uff08HR 0.334\uff1b95% CI\uff1a0.223 \u2013 0.499\uff1b<i>p <\/i>&lt;0.0001\uff09\u3002\u7d22\u51e1\u66ff\u5c3c\u5177\u6709\u53ef\u63a5\u53d7\u7684\u5b89\u5168\u6027\u7279\u5f81\uff0c\u6700\u5e38\u89c1\u7684 3 \u7ea7\u6216\u4ee5\u4e0a\u6cbb\u7597\u76f8\u5173\u4e0d\u826f\u4e8b\u4ef6\u662f\u9ad8\u8840\u538b\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005<span id=\"spanHghlt2b09\">\uff1a<\/span>36%<span id=\"spanHghlt7ca0\">\uff1b<\/span>\u5b89\u6170\u5242\u7ec4\u60a3\u8005<span id=\"spanHghlt2b09\">\uff1a<\/span>13%\uff09\u3001\u86cb\u767d\u5c3f\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005<span id=\"spanHghlt2b09\">\uff1a<\/span>19%<span id=\"spanHghlt7ca0\">\uff1b<\/span>\u5b89\u6170\u5242\u7ec4\u60a3\u8005<span id=\"spanHghlt2b09\">\uff1a<\/span>0%\uff09\u548c\u8d2b\u8840\uff08\u7d22\u51e1\u66ff\u5c3c\u7ec4\u60a3\u8005<span id=\"spanHghlt2b09\">\uff1a<\/span>5%<span id=\"spanHghlt7ca0\">\uff1b<\/span>\u5b89\u6170\u5242\u7ec4\u60a3\u8005<span id=\"spanHghlt2b09\">\uff1a<\/span>3%\uff09\u3002<\/p>\n<p><i>\u4e2d\u56fd\u80f0\u817a\u795e\u7ecf<\/i><i>\u5185<\/i><i>\u5206\u6ccc\u7624\u7814\u7a76\uff1a<\/i>\u7d22\u51e1\u66ff\u5c3c\u4e8e 2021 \u5e74 6 \u6708 18 \u65e5\u83b7\u56fd\u5bb6\u836f\u76d1\u5c40<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/nmpa-approval-of-surufatinib-for-advanced-pnet\/\" rel=\"nofollow noopener\">\u6279\u51c6<\/a>\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u3002\u6b64\u83b7\u6279\u662f\u57fa\u4e8e\u4e00\u9879\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u4e2d\u56fd III \u671f\u4e34\u5e8a\u8bd5\u9a8c SANET-p\uff08clinicaltrials.gov \u6ce8\u518c\u53f7<span id=\"spanHghlt2b09\">\uff1a<\/span><u><a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02589821\" rel=\"nofollow noopener\">NCT02589821<\/a><\/u>\uff09\u7684\u7814\u7a76\u7ed3\u679c\u3002\u8be5\u7814\u7a76\u5728\u9884\u8bbe\u7684\u4e2d\u671f\u5206\u6790\u4e2d<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/surufatinib-phase-iii-sanet-p-study-achieved-primary-endpoint\/\" rel=\"nofollow noopener\">\u6210\u529f\u8fbe\u5230 PFS \u8fd9\u4e00\u9884\u8bbe\u4e3b\u8981\u7597\u6548\u7ec8\u70b9<\/a>\uff0c\u5e76\u4ee5\u6b64\u4e3a\u57fa\u7840\u4e8e 2020 \u5e74 9 \u6708\u83b7\u56fd\u5bb6\u836f\u76d1\u5c40<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/chi-med-announces-second-nda-acceptance-in-china-for-surufatinib-in-pancreatic-net\/\" rel=\"nofollow noopener\">\u53d7\u7406<\/a>\u5176\u7b2c\u4e8c\u9879\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u3002\u8be5\u9879\u7814\u7a76\u7684\u7ed3\u679c\u5df2\u4e8e 2020 \u5e74 ESMO \u5728\u7ebf\u5e74\u4f1a\u4e0a<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/surufatinib-phase-iii-results-at-esmo-2020-and-publications-in-the-lancet-oncology\/\" rel=\"nofollow noopener\">\u516c\u5e03<\/a>\uff0c\u5e76\u540c\u6b65<a target=\"_blank\" href=\"https:\/\/www.thelancet.com\/journals\/lanonc\/article\/PIIS1470-2045(20)30493-9\/fulltext\" rel=\"nofollow noopener\">\u53d1\u8868<\/a>\u4e8e\u300a\u67f3\u53f6\u5200<span id=\"spanHghltf0ae\">&#8211;<\/span>\u80bf\u7624\u5b66\u300b<sup><span id=\"spanHghlt2c9a\">[6]<\/span><\/sup>\uff0c\u8bc1\u660e\u7d22\u51e1\u66ff\u5c3c\u5c06\u60a3\u8005\u75be\u75c5\u8fdb\u5c55\u6216\u6b7b\u4ea1\u98ce\u9669\u964d\u4f4e\u4e8651%\uff0c\u4e2d\u4f4d PFS \u4e3a 10.9 \u4e2a\u6708\uff0c\u800c\u5b89\u6170\u5242\u7ec4\u60a3\u8005\u5219\u4e3a 3.7 \u4e2a\u6708\uff08HR 0.491\uff1b95% CI\uff1a0.391-0.755\uff1b<i>p&nbsp;<\/i>= 0.0011\uff09\u3002 \u7d22\u51e1\u66ff\u5c3c\u5c55\u793a\u53ef\u63a7\u7684\u5b89\u5168\u6027\uff0c\u5e76\u4e0e\u5148\u524d\u7814\u7a76\u4e2d\u7684\u89c2\u5bdf\u7ed3\u679c\u4e00\u81f4\u3002<\/p>\n<p><i>\u4e2d\u56fd\u80c6\u9053\u764c\u7814\u7a76\uff1a<\/i>\u548c\u9ec4\u533b\u836f\u4e8e 2019 \u5e74 3 \u6708\u542f\u52a8\u4e86\u4e00\u9879 IIb\/III \u671f\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u65e8\u5728\u5bf9\u6bd4\u7ecd\u51e1\u66ff\u5c3c\u548c\u5361\u57f9\u4ed6\u6ee8\u6cbb\u7597\u4e00\u7ebf\u5316\u7597\u540e\u8fdb\u5c55\u7684\u665a\u671f\u80c6\u9053\u764c\u60a3\u8005\u3002\u8be5\u7814\u7a76\u7684\u4e3b\u8981\u7ec8\u70b9\u4e3a\u603b\u751f\u5b58\u671f\uff08\u201cOS\u201d\uff09\uff08clinicaltrials.gov \u6ce8\u518c\u53f7\uff1a<u><a target=\"_blank\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03873532\" rel=\"nofollow noopener\">NCT03873532<\/a><\/u>\uff09\u3002<\/p>\n<p><i>\u514d\u75ab\u8054\u5408<\/i><i>\u7597<\/i><i>\u6cd5\uff1a<\/i>\u548c\u9ec4\u533b\u836f\u8fbe\u6210\u4e86\u6570\u4e2a\u5408\u4f5c\u534f\u8bae\uff0c\u4ee5\u8bc4\u4f30\u7d22\u51e1\u66ff\u5c3c\u4e0e PD-1 \u5355\u514b\u9686\u6297\u4f53\u8054\u5408\u7597\u6cd5\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u7597\u6548\uff0c\u5305\u62ec\u5df2\u4e8e\u4e2d\u56fd\u83b7\u6279\u5355\u836f\u7597\u6cd5\u7684<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/chi-med-and-beigene-collaboration-to-evaluate-surufatinib-and-fruquintinib-with-tislelizumab-combinations\/\" rel=\"nofollow noopener\">\u66ff\u96f7\u5229\u73e0\u5355\u6297<\/a>\uff08BGB-A317\uff09\u3001<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/chi-med-initiates-a-phase-ii-trial-of-surufatinib-in-combination-with-tuoyi-in-patients-with-advanced-solid-tumors\/\" rel=\"nofollow noopener\">\u62d3\u76ca&reg;<\/a>\uff08\u7279\u745e\u666e\u5229\u5355\u6297\uff09\u548c<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/innovent-and-chi-med-expand-global-collaboration-to-evaluate-the-combination-of-sintilimab-and-surufatinib-in-solid-tumors\/\" rel=\"nofollow noopener\">\u8fbe\u4f2f\u8212&reg;<\/a>\uff08\u4fe1\u8fea\u5229\u5355\u6297\uff09\u3002<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prnbcc\">\n<tbody>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[1] <u>S<\/u>urufatinib in <u>a<\/u>dvanced <u>n<\/u>euro<u>e<\/u>ndocrine <u>t<\/u>umors \u2013 <u>p<\/u>ancreatic. (\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[2]&nbsp;<u>S<\/u>urufatinib in <u>a<\/u>dvanced <u>n<\/u>euro<u>e<\/u>ndocrine <u>t<\/u>umors \u2013 <u>e<\/u>xtra-<u>p<\/u>ancreatic (non-pancreatic). (\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u665a\u671f\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[3]&nbsp;Fraenkel M, Kim M, Faggiano A, de Herder WW, Valk GD; Knowledge NETwork. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature.&nbsp;<i>Endocr Relat Cancer<\/i>. 2014;21(3):R153-R163. Published 2014 May 6. doi:<a target=\"_blank\" href=\"https:\/\/doi.org\/10.1530\/ERC-13-0125\" class=\"prnews_a\" rel=\"nofollow noopener\">10.1530\/ERC-13-0125<\/a>.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[4]&nbsp;\u6839\u636eFrost &amp; Sullivan\u516c\u53f8\u7684\u6570\u636e\uff0c2020\u5e74\u7f8e\u56fd\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u65b0\u8bca\u65ad\u75c5\u4f8b\u4e3a19,000\u4f8b\uff0c\u7f8e\u56fd\u7684\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u603b\u6570\u7ea6\u4e3a143,000\u540d\u3002<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[5]&nbsp;Xu J, Shen L, Zhou Z, et al. Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. <i>Lancet Oncol.<\/i> 2020; S1470-2045(20)30496-4. <a target=\"_blank\" href=\"https:\/\/doi.org\/10.1016\/S1470-2045(20)30496-4\" class=\"prnews_a\" rel=\"nofollow noopener\">DOI: 10.1016\/S1470-2045(20)30496-4<\/a>.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\"><span class=\"prnews_span\">[6]&nbsp;Xu J, Shen L, Bai C, et al. Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study [published online ahead of print, 2020 Sep 20]. <i>Lancet Oncol.<\/i> 2020;&nbsp;S1470-2045(20)30493-9. <a target=\"_blank\" href=\"https:\/\/doi.org\/10.1016\/S1470-2045(20)30493-9\" class=\"prnews_a\" rel=\"nofollow noopener\">DOI: 10.1016\/S1470-2045(20)30493-9<\/a>.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n<p><b>\u5173\u4e8e\u548c\u9ec4\u533b\u836f<\/b><\/p>\n<p>\u548c\u9ec4\u533b\u836f\uff08\u7eb3\u65af\u8fbe\u514b\/\u4f26\u6566\u8bc1\u4ea4\u6240\uff1aHCM\uff1b\u9999\u6e2f\u4ea4\u6613\u6240\uff1a13\uff09\u662f\u4e00\u5bb6\u5904\u4e8e\u5546\u4e1a\u5316\u9636\u6bb5\u7684\u521b\u65b0\u578b\u751f\u7269\u533b\u836f\u516c\u53f8\uff0c\u81f4\u529b\u4e8e\u53d1\u73b0\u3001\u5168\u7403\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u6cbb\u7597\u764c\u75c7\u548c\u514d\u75ab\u6027\u75be\u75c5\u7684\u9776\u5411\u836f\u7269\u548c\u514d\u75ab\u7597\u6cd5\u3002\u8d85\u8fc7 1,300 \u4eba\u7684\u4e13\u4e1a\u56e2\u961f\u5df2\u5c06\u81ea\u4e3b\u53d1\u73b0\u7684 10 \u4e2a\u5019\u9009\u764c\u75c7\u836f\u7269\u63a8\u8fdb\u5230\u5728\u5168\u7403\u5f00\u5c55\u4e34\u5e8a\u7814\u7a76\uff0c\u5176\u4e2d\u9996\u4e09\u4e2a\u521b\u65b0\u80bf\u7624\u836f\u7269\u73b0\u5df2\u83b7\u6279\u4e0a\u5e02\u3002\u6b32\u4e86\u89e3\u66f4\u591a\u8be6\u60c5\uff0c\u8bf7\u8bbf\u95ee\uff1a<a target=\"_blank\" href=\"https:\/\/www.hutch-med.com\/sc\/home\/\" rel=\"nofollow noopener\">http:\/\/www.hutch-med.com<\/a>&nbsp;\u6216\u5173\u6ce8\u6211\u4eec\u7684<a target=\"_blank\" href=\"https:\/\/www.linkedin.com\/authwall?trk=bf&amp;trkInfo=AQEp4EeReyQgqwAAAXp2GSQIFserNQ_a519smGkGCjQG9aLoZU6NJ48KdQ3aoM5scSVJ4JXAECL4SJyWxuWGLoU_xASWwpuILFJHrdeyImMT_x9U2OH1puqlEO5T2qeamMqUVoo=&amp;originalReferer=&amp;sessionRedirect=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fhutchmed%2F\" rel=\"nofollow noopener\">\u9886\u82f1\u4e13\u9875<\/a>\u3002<\/p>\n<p><b><i>\u524d\u77bb\u6027<\/i><i>\u9648<\/i><i>\u8ff0<\/i><\/b><\/p>\n<p><i>\u672c\u65b0<\/i><i>\u95fb<\/i><i>\u7a3f\u5305\u542b <\/i><i>1995 \u5e74\u300a\u7f8e\u56fd\u79c1\u4eba<\/i><i>\u8bc1<\/i><i>\u5238<\/i><i>\u8bc9\u8bbc<\/i><i>\u6539\u9769\u6cd5\u6848\u300b<\/i><i>\u201c\u5b89\u5168\u6e2f\u201d\u6761\u6b3e\u4e2d\u5b9a\u4e49\u7684\u524d\u77bb\u6027<\/i><i>\u9648<\/i><i>\u8ff0\u3002<\/i><i>\u8fd9<\/i><i>\u4e9b\u524d\u77bb\u6027<\/i><i>\u9648<\/i><i>\u8ff0\u53cd\u6620\u4e86\u548c\u9ec4\u533b\u836f\u76ee\u524d<\/i><i>\u5bf9<\/i><i>\u672a<\/i><i>\u6765<\/i><i>\u4e8b\u4ef6\u7684<\/i><i>\u9884<\/i><i>\u671f\uff0c<\/i><i>\u5305\u62ec<\/i><i>\u6b27<\/i><i>\u6d32\u836f\u54c1\u7ba1\u7406\u5c40<\/i><i>\u5ba1\u8bc4<\/i><i>\u7d22\u51e1\u66ff\u5c3c\u7528\u4e8e\u6cbb<\/i><i>\u7597<\/i><i>\u795e\u7ecf<\/i><i>\u5185<\/i><i>\u5206\u6ccc\u7624\u7684<\/i><i>\u4e0a\u5e02<\/i><i>\u8bb8<\/i><i>\u53ef\u7533<\/i><i>\u8bf7<\/i><i>\u4ee5\u53ca<\/i><i>\u5ba1\u8bc4\u65f6<\/i><i>\u95f4<\/i><i>\u7684<\/i><i>\u9884<\/i><i>\u671f<\/i><i>\uff0c\u7d22\u51e1\u66ff\u5c3c\u7528\u4e8e\u6cbb<\/i><i>\u7597<\/i><i>\u795e\u7ecf<\/i><i>\u5185<\/i><i>\u5206\u6ccc\u7624\u60a3\u8005\u7684\u6cbb<\/i><i>\u7597<\/i><i>\u6f5c\u529b\u7684<\/i><i>\u9884<\/i><i>\u671f<\/i><i>\u4ee5\u53ca\u7d22\u51e1\u66ff\u5c3c<\/i><i>\u9488\u5bf9<\/i><i>\u6b64\u9002<\/i><i>\u5e94<\/i><i>\u75c7\u53ca\u5176\u4ed6\u9002<\/i><i>\u5e94<\/i><i>\u75c7\u7684<\/i><i>\u8fdb<\/i><i>\u4e00\u6b65<\/i><i>\u4e34<\/i><i>\u5e8a\u7814\u7a76<\/i><i>\u8ba1<\/i><i>\u5212<\/i><i>\u3002\u524d\u77bb\u6027<\/i><i>\u9648<\/i><i>\u8ff0\u6d89\u53ca\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u3002<\/i><i>\u6b64\u7c7b\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u5305\u62ec\u4e0b\u5217\u5047\u8bbe\uff1a\u652f\u6301\u7d22\u51e1\u66ff\u5c3c<\/i><i>\u83b7<\/i><i>\u6279\u7528\u4e8e\u5728\u7f8e\u56fd\u3001\u4e2d\u56fd\u53ca\u5176\u4ed6\u5730<\/i><i>\u533a<\/i><i>\uff08\u5982<\/i><i>\u6b27<\/i><i>\u6d32\uff09\u6cbb<\/i><i>\u7597<\/i><i>\u795e\u7ecf<\/i><i>\u5185<\/i><i>\u5206\u6ccc\u7624\u7684\u65b0\u836f\u4e0a\u5e02\u7533<\/i><i>\u8bf7<\/i><i>\u7684<\/i><i>\u6570<\/i><i>\u636e\u5145\u8db3\u6027\u3001<\/i><i>\u83b7<\/i><i>\u5f97<\/i><i>\u76d1<\/i><i>\u7ba1\u90e8\u95e8\u5feb\u901f<\/i><i>\u5ba1<\/i><i>\u6279\u7684\u6f5c\u529b\uff0c\u7d22\u51e1\u66ff\u5c3c\u7684\u5b89\u5168\u6027\u3002<\/i><i>\u548c\u9ec4\u533b\u836f<\/i><i>\u4e3a<\/i><i>\u7d22\u51e1\u66ff\u5c3c<\/i><i>\u8fdb<\/i><i>\u4e00\u6b65<\/i><i>\u4e34<\/i><i>\u5e8a<\/i><i>\u5f00<\/i><i>\u53d1<\/i><i>\u8ba1<\/i><i>\u5212<\/i><i>\u53ca\u5546\u4e1a\u5316\u63d0\u4f9b<\/i><i>\u8d44<\/i><i>\u91d1\u5e76\u5b9e<\/i><i>\u73b0<\/i><i>\u53ca\u5b8c\u6210\u7684\u80fd\u529b\uff0c\u6b64\u7c7b\u4e8b\u4ef6\u53d1\u751f\u7684<\/i><i>\u65f6<\/i><i>\u95f4\uff0c\u4ee5\u53ca\u65b0\u51a0\u80ba\u708e\u5168\u7403\u5927\u6d41\u884c<\/i><i>\u5bf9<\/i><i>\u6574\u4f53\u7ecf\u6d4e\u3001<\/i><i>\u76d1<\/i><i>\u7ba1\u53ca\u653f\u6cbb<\/i><i>\u72b6<\/i><i>\u51b5<\/i><i>\u5e26\u6765<\/i><i>\u7684\u5f71\u54cd\u7b49\u3002<\/i><i>\u6b64\u5916\uff0c\u7531\u4e8e\u90e8\u5206\u7814\u7a76<\/i><i>\u8d56<\/i><i>\u4e8e<\/i><i>\u5c06<\/i><i>\u5361\u57f9\u4ed6\u6ee8\u3001\u66ff\u96f7\u5229\u73e0<\/i><i>\u5355<\/i><i>\u6297\u3001\u62d3\u76ca<\/i><i>&reg;\u3001\u8fbe\u4f2f\u8212&reg;\u4e0e\u7d22\u51e1\u66ff\u5c3c\u8054\u5408\u4f7f\u7528\uff0c\u56e0\u6b64\u6b64\u7c7b\u98ce\u9669\u548c\u4e0d\u786e\u5b9a\u6027\u5305\u62ec\u6709<\/i><i>\u5173\u8fd9<\/i><i>\u4e9b\u6cbb<\/i><i>\u7597<\/i><i>\u836f\u7269\u7684\u5b89\u5168\u6027\u3001<\/i><i>\u7597<\/i><i>\u6548\u3001\u4f9b<\/i><i>\u5e94<\/i><i>\u548c<\/i><i>\u76d1<\/i><i>\u7ba1<\/i><i>\u6279\u51c6\u7684\u5047\u8bbe\u3002<\/i><i>\u5f53<\/i><i>\u524d\u548c\u6f5c\u5728\u6295<\/i><i>\u8d44<\/i><i>\u8005<\/i><i>\u8bf7<\/i><i>\u52ff<\/i><i>\u8fc7<\/i><i>\u5ea6\u4f9d<\/i><i>\u8d56\u8fd9<\/i><i>\u4e9b<\/i><i>\u524d\u77bb\u6027<\/i><i>\u9648<\/i><i>\u8ff0\uff0c<\/i><i>\u8fd9<\/i><i>\u4e9b<\/i><i>\u9648<\/i><i>\u8ff0<\/i><i>\u4ec5<\/i><i>\u5728\u622a\u81f3\u672c<\/i><i>\u65b0<\/i><i>\u95fb<\/i><i>\u7a3f<\/i><i>\u53d1\u5e03<\/i><i>\u5f53<\/i><i>\u65e5\u6709\u6548\u3002<\/i><i>\u6709<\/i><i>\u5173\u8fd9<\/i><i>\u4e9b\u98ce\u9669\u548c\u5176\u4ed6\u98ce\u9669\u7684<\/i><i>\u8fdb<\/i><i>\u4e00\u6b65<\/i><i>\u8ba8\u8bba<\/i><i>\uff0c<\/i><i>\u8bf7<\/i><i>\u67e5<\/i><i>\u9605<\/i><i>\u548c\u9ec4\u533b\u836f\u5411\u7f8e\u56fd<\/i><i>\u8bc1<\/i><i>\u5238\u4ea4\u6613\u59d4<\/i><i>\u5458<\/i><i>\u4f1a\u3001<\/i><i>AIM \u4ee5\u53ca\u9999\u6e2f\u8054\u5408\u4ea4\u6613\u6240\u6709\u9650\u516c\u53f8\u63d0\u4ea4\u7684\u6587\u4ef6\u3002\u65e0<\/i><i>\u8bba<\/i><i>\u662f\u5426\u51fa<\/i><i>\u73b0<\/i><i>\u65b0<\/i><i>\u8baf<\/i><i>\u606f\u3001\u672a<\/i><i>\u6765<\/i><i>\u4e8b\u4ef6\u6216\u60c5\u51b5\u6216\u5176\u4ed6\u56e0\u7d20\uff0c\u548c\u9ec4\u533b\u836f\u5747\u4e0d\u627f\u62c5\u66f4\u65b0\u6216\u4fee<\/i><i>\u8ba2<\/i><i>\u672c\u65b0<\/i><i>\u95fb<\/i><i>\u7a3f\u6240\u542b<\/i><i>\u8baf<\/i><i>\u606f\u7684\u4e49\u52a1\u3002<\/i><\/p>\n<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">  <\/div>\n<p>\u76f8\u5173\u94fe\u63a5 :<\/p>\n<blockquote class=\"wp-embedded-content\" data-secret=\"YWArANtgtB\"><p><a href=\"https:\/\/www.hutch-med.com\/\">Home<\/a><\/p><\/blockquote>\n<p><iframe class=\"wp-embedded-content\" sandbox=\"allow-scripts\" security=\"restricted\" style=\"position: absolute; clip: rect(1px, 1px, 1px, 1px);\" title=\"&#8220;Home&#8221; &#8212; HUTCHMED\" src=\"https:\/\/www.hutch-med.com\/embed\/#?secret=YWArANtgtB\" data-secret=\"YWArANtgtB\" width=\"600\" height=\"338\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\"><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; \u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\u5f00\u59cb\u5ba1\u8bc4\u7d22\u51e1\u66ff\u5c3c\u7528\u4e8e\u6cbb\u7597\u665a\u671f\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7 &#8211; -\u7ee7\u7d22\u51e1\u66ff\u5c3c\u4e8e\u4e2d\u56fd\u4e0a\u5e02\u4ee5\u53ca\u7f8e\u56fd\u7684\u4e0a\u5e02\u7533\u8bf7\u8fdb\u5165\u5ba1\u8bc4\u9636\u6bb5\u540e\uff0c\u8fdb\u4e00\u6b65\u6269\u5927\u4e86\u5176\u6f5c\u5728\u5168\u7403\u53ef\u53ca\u8303\u56f4- \u9999\u6e2f2021\u5e747\u670816\u65e5 \/\u7f8e\u901a\u793e\/ &#8212; \u548c\u9ec4\u533b\u836f\uff08\u4e2d\u56fd\uff09\u6709\u9650\u516c\u53f8\uff08\u7b80\u79f0\u201c\u548c\u9ec4\u533b\u836f\u201d\u6216\u201cHUTCHMED\u201d\uff09\uff08\u7eb3\u65af\u8fbe\u514b\/\u4f26\u6566\u8bc1\u4ea4\u6240\uff1aHCM\uff1b\u9999\u6e2f\u4ea4\u6613\u6240\uff1a13\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08\u201cEMA\u201d\uff09\u5df2\u786e\u8ba4\u5e76\u53d7\u7406\u7d22\u51e1\u66ff\u5c3c\u7528\u4e8e\u6cbb\u7597\u80f0\u817a\u548c\u80f0\u817a\u5916\uff08\u975e\u80f0\u817a\uff09\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08NET\uff09\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\uff08MAA\uff09\u3002EMA \u5df2\u786e\u8ba4\u63d0\u4ea4\u6750\u6599\u7684\u5b8c\u6574\u6027\uff0c\u5e76\u4e14\u5df2\u51c6\u5907\u597d\u542f\u52a8\u6b63\u5f0f\u7684\u5ba1\u8bc4\u7a0b\u5e8f\u3002 \u8be5\u7533\u8bf7\u63d0\u4ea4\u662f\u9075\u5faa\u4e86 EMA \u4eba\u7528\u836f\u54c1\u59d4\u5458\u4f1a\uff08\u201cCHMP\u201d\uff09\u63d0\u4f9b\u7684\u79d1\u5b66\u5efa\u8bae\uff0c\u5176\u7ed3\u8bba\u4e3a\uff1a\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u80f0\u817a\u548c\u975e\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u4e24\u9879\u6210\u529f\u7684\u4e2d\u56fd&nbsp;III \u671f\u7814\u7a76\uff08SANET-p[1]&nbsp;\u53ca SANET-ep[2]&nbsp;\uff0c\u4e24\u9879\u7814\u7a76\u7ed3\u679c\u5747\u5df2\u4e8e\u300a\u67f3\u53f6\u5200&#8211;\u80bf\u7624\u5b66\u300b\u671f\u520a\u4e0a\u520a\u767b\uff09\u4ee5\u53ca\u7d22\u51e1\u66ff\u5c3c\u6cbb\u7597\u7f8e\u56fd\u975e\u80f0\u817a\u548c\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u7684\u73b0\u6709\u6570\u636e\uff0c\u53ef\u4ee5\u4f5c\u4e3a\u652f\u6301\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u7684\u4f9d\u636e\u3002\u548c\u9ec4\u533b\u836f\u5df2\u4e8e&nbsp;2021 \u5e74 7 \u6708 1 \u65e5\u5ba3\u5e03\u5411\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08\u201cFDA\u201d\uff09\u63d0\u4ea4\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u5e76\u83b7\u53d7\u7406\u3002 \u548c\u9ec4\u533b\u836f\uff08\u56fd\u9645\uff09\u8463\u4e8b\u603b\u7ecf\u7406\u517c\u9996\u5e2d\u533b\u5b66\u5b98 Marek Kania \u533b\u5b66\u535a\u58eb\u8868\u793a\uff1a\u201c\u548c\u9ec4\u533b\u836f\u7684\u521b\u65b0\u80bf\u7624\u836f\u7269\u7ba1\u7ebf\u6b63\u5728\u5168\u7403\u8303\u56f4\u5185\u53d6\u5f97\u91cd\u8981\u7684\u8fdb\u5c55\u3002\u7ee7\u7f8e\u56fd FDA \u53d7\u7406\u7d22\u51e1\u66ff\u5c3c\u7684\u7f8e\u56fd\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u540e\uff0c\u6211\u4eec\u76f8\u4fe1\u6b64\u6b21 EMA \u5bf9\u8be5\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u7684\u786e\u8ba4\uff0c\u8ba4\u53ef\u4e86\u76f8\u5173\u7533\u8bf7\u6750\u6599\u7684\u79d1\u5b66\u4ef7\u503c\u3002\u4eca\u5e74\u65e9\u4e9b\u65f6\u5019\uff0c\u7d22\u51e1\u66ff\u5c3c\u4e8e\u4e2d\u56fd\u4e0a\u5e02\uff0c\u4e3a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u63d0\u4f9b\u4e86\u91cd\u8981\u7684\u6cbb\u7597\u65b0\u9009\u62e9\uff0c\u73b0\u5728\u6211\u4eec\u5e0c\u671b\u5f88\u5feb\u80fd\u591f\u5c06\u8fd9\u79cd\u91cd\u8981\u7684\u6cbb\u7597\u65b9\u6cd5\u5e26\u5411\u7f8e\u56fd\u548c\u6b27\u6d32\u7684\u60a3\u8005\u3002\u201d \u5173\u4e8e\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08NET\uff09 \u795e\u7ecf\u5185\u5206\u6ccc\u7624\u8d77\u6e90\u4e8e\u4e0e\u795e\u7ecf\u7cfb\u7edf\u76f8\u4e92\u4f5c\u7528\u7684\u7ec6\u80de\u6216\u4ea7\u751f\u6fc0\u7d20\u7684\u817a\u4f53\u3002\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u53ef\u8d77\u6e90\u4e8e\u4f53\u5185\u5404\u4e2a\u90e8\u4f4d\uff0c\u6700\u5e38\u89c1\u4e8e\u6d88\u5316\u9053\u6216\u80ba\u90e8\uff0c\u53ef\u4e3a\u826f\u6027\u6216\u6076\u6027\u80bf\u7624\u3002\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u901a\u5e38\u5206\u4e3a\u80f0\u817a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08pNET\uff09\u548c\u80f0\u817a\u5916\uff08\u975e\u80f0\u817a\uff09\u795e\u7ecf\u5185\u5206\u6ccc\u7624\uff08epNET\uff09\u3002 \u636e&nbsp;Frost &amp; Sullivan \u516c\u53f8\u4f30\u8ba1\uff0c2020 \u5e74\u7f8e\u56fd\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u65b0\u8bca\u65ad\u75c5\u4f8b\u4e3a&nbsp;19,000 \u4f8b\u3002\u57fa\u4e8e\u5168\u7403\u6d41\u884c\u75c5\u5b66\u8d8b\u52bf\u7684\u5206\u6790\uff0c\u6574\u4e2a\u6b27\u76df&nbsp;(EU) \u7684\u53d1\u75c5\u7387\u4e0e\u7f8e\u56fd\u5927\u81f4\u76f8\u8fd1\uff0c\u800c\u8be5\u5206\u6790\u540c\u65f6\u663e\u793a\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u5168\u7403\u53d1\u75c5\u7387\u5448\u4e0a\u5347\u8d8b\u52bf\u3002[3]&nbsp;\u91cd\u8981\u7684\u662f\uff0c\u4e0e\u5176\u4ed6\u80bf\u7624\u76f8\u6bd4\uff0c\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7684\u751f\u5b58\u671f\u76f8\u5bf9\u8f83\u957f\u3002&nbsp;\u56e0\u6b64\uff0c\u636e\u4f30\u8ba12020 \u5e74\u6cd5\u56fd\u3001\u5fb7\u56fd\u3001\u610f\u5927\u5229\u3001\u897f\u73ed\u7259\u548c\u82f1\u56fd\u7ea6\u6709&nbsp;140,000 \u540d\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u60a3\u8005\u3002[4] \u5173\u4e8e\u7d22\u51e1\u66ff\u5c3c \u7d22\u51e1\u66ff\u5c3c\uff08surufatinib\uff09\u662f\u4e00\u79cd\u65b0\u578b\u7684\u53e3\u670d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5242\uff0c\u5177\u6709\u6297\u8840\u7ba1\u751f\u6210\u548c\u514d\u75ab\u8c03\u8282\u53cc\u91cd\u6d3b\u6027\u3002\u7d22\u51e1\u66ff\u5c3c\u53ef\u901a\u8fc7\u6291\u5236\u8840\u7ba1\u5185\u76ae\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08VEGFR\uff09\u548c\u6210\u7ea4\u7ef4\u7ec6\u80de\u751f\u957f\u56e0\u5b50\u53d7\u4f53\uff08FGFR\uff09\u4ee5\u963b\u65ad\u80bf\u7624\u8840\u7ba1\u751f\u6210\uff0c&nbsp;\u5e76\u53ef\u6291\u5236\u96c6\u843d\u523a\u6fc0\u56e0\u5b50&nbsp;1 \u53d7\u4f53\uff08CSF-1R\uff09\uff0c\u901a\u8fc7\u8c03\u8282\u80bf\u7624\u76f8\u5173\u5de8\u566c\u7ec6\u80de\uff0c\u4fc3\u8fdb\u673a\u4f53\u5bf9\u80bf\u7624\u7ec6\u80de\u7684\u514d\u75ab\u5e94\u7b54\u3002\u7d22\u51e1\u66ff\u5c3c\u72ec\u7279\u7684\u53cc\u91cd\u673a\u5236\u80fd\u4ea7\u751f\u534f\u540c\u6297\u80bf\u7624\u6d3b\u6027\uff0c\u4f7f\u5176\u4e3a\u4e0e\u5176\u4ed6\u514d\u75ab\u7597\u6cd5\u7684\u8054\u5408\u4f7f\u7528\u7684\u7406\u60f3\u9009\u62e9\u3002 \u548c\u9ec4\u533b\u836f\u76ee\u524d\u62e5\u6709\u7d22\u51e1\u66ff\u5c3c\u5728\u5168\u7403\u8303\u56f4\u5185\u7684\u6240\u6709\u6743\u5229\u3002 \u7d22\u51e1\u66ff\u5c3c\u5f00\u53d1\u8ba1\u5212 \u7f8e\u56fd\u4e0e\u6b27\u6d32\u795e\u7ecf\u5185\u5206\u6ccc\u7624\u7814\u7a76\uff1a\u7d22\u51e1\u66ff\u5c3c\u7684\u7f8e\u56fd\u65b0\u836f\u4e0a\u5e02\u7533\u8bf7\u5df2\u4e8e 2021 \u5e74 6 \u6708\u83b7 FDA \u53d7\u7406\uff0c\u5411 EMA \u63d0\u4ea4\u7684\u4e0a\u5e02\u8bb8\u53ef\u7533\u8bf7\u4ea6\u4e8e&nbsp;2021 \u5e74 7 \u6708\u83b7\u786e\u8ba4\u3002\u4ee5\u4e0a\u7533\u8bf7\u5747\u662f\u57fa\u4e8e\u5df2\u5b8c\u6210\u7684&hellip; <a class=\"read-more\" href=\"https:\/\/www.xinwengao.com\/cn\/pr\/2021071611500037576\">Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":37579,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-37576","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/37576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=37576"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/37576\/revisions"}],"predecessor-version":[{"id":37578,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/37576\/revisions\/37578"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/37579"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=37576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=37576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=37576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}